DE60124504D1 - Stabile emulsionszubereitungen - Google Patents

Stabile emulsionszubereitungen

Info

Publication number
DE60124504D1
DE60124504D1 DE60124504T DE60124504T DE60124504D1 DE 60124504 D1 DE60124504 D1 DE 60124504D1 DE 60124504 T DE60124504 T DE 60124504T DE 60124504 T DE60124504 T DE 60124504T DE 60124504 D1 DE60124504 D1 DE 60124504D1
Authority
DE
Germany
Prior art keywords
substituents
hydrocarbon group
group optionally
aliphatic hydrocarbon
chem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60124504T
Other languages
English (en)
Other versions
DE60124504T2 (de
Inventor
Jun Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60124504D1 publication Critical patent/DE60124504D1/de
Publication of DE60124504T2 publication Critical patent/DE60124504T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/14—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
DE60124504T 2000-02-04 2001-02-01 Stabile emulsionszubereitungen Expired - Lifetime DE60124504T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000032720 2000-02-04
JP2000032720 2000-02-04
PCT/JP2001/000705 WO2001056562A1 (fr) 2000-02-04 2001-02-01 Compositions d'emulsions stables

Publications (2)

Publication Number Publication Date
DE60124504D1 true DE60124504D1 (de) 2006-12-28
DE60124504T2 DE60124504T2 (de) 2007-09-20

Family

ID=18557283

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60124504T Expired - Lifetime DE60124504T2 (de) 2000-02-04 2001-02-01 Stabile emulsionszubereitungen

Country Status (9)

Country Link
US (1) US7105572B2 (de)
EP (1) EP1254659B1 (de)
KR (1) KR100784752B1 (de)
CN (1) CN1416341B (de)
AT (1) ATE345122T1 (de)
AU (1) AU776851B2 (de)
CA (1) CA2400804C (de)
DE (1) DE60124504T2 (de)
WO (1) WO2001056562A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046242A1 (fr) 1998-03-09 1999-09-16 Takeda Chemical Industries, Ltd. Derives de cycloalcene, leur procede de fabrication et d'utilisation
AU2001278705A1 (en) * 2000-08-10 2002-02-25 Takeda Chemical Industries Ltd. Pharmaceutical composition
EP1348443A4 (de) * 2000-12-08 2005-07-06 Takeda Pharmaceutical Kombinationsmedikamente
EP1420783A4 (de) * 2001-08-03 2009-09-30 Takeda Pharmaceutical Stabile emulsionszusammensetzung
EP1495756A4 (de) * 2002-04-08 2009-10-28 Takeda Pharmaceutical Therapeutikum zur prävention schwerer sepsis
EP1608378A1 (de) * 2003-04-02 2005-12-28 Nexmed (Holdings), Inc. Prostaglandin-zusammensetzungen und ihre verwendung zur behandlung von vasospasmus
KR101535395B1 (ko) 2004-01-22 2015-07-08 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (de) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Verwendung von PDE III Ihibitoren zur Reduktion der Herzgrösse in an Herzversagen leidenden Säugern
US8980894B2 (en) * 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US20070299041A1 (en) * 2004-05-26 2007-12-27 Cedars-Sinai Medical Center Induction of innate immunity by vitamin d3 and its analogs
US20060160823A1 (en) * 2004-05-28 2006-07-20 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmaceutical compositions of Posaconazole
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
WO2006135415A2 (en) * 2004-09-08 2006-12-21 University Of Florida Research Foundation, Inc. Micelles and nanoemulsions for preventative and reactive treatment of atherosclerosis
US20060188470A1 (en) * 2005-02-22 2006-08-24 Livingston William H PES 2000 plus folic acid
MY147790A (en) * 2005-04-28 2013-01-31 Takeda Pharmaceutical Stable emulsion composition
US20090209585A1 (en) * 2006-07-07 2009-08-20 Takashi Ichikawa Cycloalkene derivatives, process for production of the derivatives, and use of the same
EP1920785A1 (de) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Pimobendan-Cyclodextrin Komplex enthaltendes flüssiges Präparat
US20080234376A1 (en) * 2007-03-21 2008-09-25 Taiwan Liposome Company (A Taiwan Corporation) Emulsion composition comprising prostaglandin e1
US20100048740A1 (en) * 2007-04-13 2010-02-25 Michel Mercier Naturally Derived Emulsifier System
EP2271325A4 (de) 2008-04-11 2011-11-09 Cytotech Labs Llc Verfahren und verfwendung zur einleitung von apoptose bei krebszellen
US20110159152A1 (en) * 2008-06-02 2011-06-30 Niigata University Microcapsules, method of producing the microcapsules and food and drink containing the microcapsules
KR20120034649A (ko) 2009-05-11 2012-04-12 버그 바이오시스템즈, 엘엘씨 환경대사적 전환인자（조효소 ｑ１０）를 사용한 질환의 치료 방법
MA34014B1 (fr) 2010-01-27 2013-02-01 Takeda Pharmaceutical Composés permettant de réprimer un trouble nerveux périphérique induit par un agent anticancéreux
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
ES2762451T3 (es) 2011-04-04 2020-05-25 Berg Llc Tratamiento de tumores del sistema nervioso central con coenzima Q10
US8940794B2 (en) 2011-04-07 2015-01-27 Nexmed Holdings, Inc. Methods and compositions for treating Raynaud's disease
RU2450807C1 (ru) * 2011-05-11 2012-05-20 Общество с ограниченной ответственностью фирма "Вита" Стабилизированный фармацевтический состав с противогрибковым действием
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
FR2991879B1 (fr) * 2012-06-14 2014-11-21 Ethypharm Sa Formulation pharmaceutique orale de molecules bcs de classe iii
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
PL2911525T3 (pl) * 2012-10-24 2020-05-18 Cargill, Incorporated Kompozycja emulgatora zawierająca fosfolipidy
EA032775B1 (ru) 2013-04-08 2019-07-31 Берг Ллк Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
EA034430B1 (ru) 2013-07-19 2020-02-06 Бёрингер Ингельхайм Ветмедика Гмбх Жидкая водная фармацевтическая композиция с консервантами, содержащая этерифицированные производные циклодекстрина
JP6595478B2 (ja) 2013-09-04 2019-10-23 バーグ エルエルシー コエンザイムｑ１０の連続注入によるがんの治療方法
ES2883448T3 (es) 2013-12-04 2021-12-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmacéuticas mejoradas de pimobendán
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
DK3157936T3 (en) 2014-06-18 2019-02-04 Thetis Pharmaceuticals Llc MINERAL AMINO ACID ACID COMPLEXES OF ACTIVE SUBSTANCES
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
CN106508679A (zh) * 2016-11-08 2017-03-22 许焕明 一种提高生物碱的铁皮石斛组培苗培养基及其制备方法
CN106386502A (zh) * 2016-11-08 2017-02-15 许焕明 一种铁皮石斛组培苗培养基及其制备方法
CN106417032A (zh) * 2016-11-08 2017-02-22 许焕明 一种提高氨基酸的铁皮石斛组培苗培养基及其制备方法
CN114364371A (zh) * 2019-07-16 2022-04-15 金德雷德生物科学股份有限公司 马科动物埃索美拉唑配制品及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05229941A (ja) * 1992-02-26 1993-09-07 Takeda Chem Ind Ltd フェノール誘導体を含有する注射用乳剤
EP0746318A1 (de) * 1994-02-25 1996-12-11 Takeda Chemical Industries, Ltd. Injizierbare emulsionen enthaltend fungizide triazolderivate
WO1999046242A1 (fr) * 1998-03-09 1999-09-16 Takeda Chemical Industries, Ltd. Derives de cycloalcene, leur procede de fabrication et d'utilisation

Also Published As

Publication number Publication date
KR100784752B1 (ko) 2007-12-13
ATE345122T1 (de) 2006-12-15
KR20030016224A (ko) 2003-02-26
EP1254659B1 (de) 2006-11-15
AU2886601A (en) 2001-08-14
EP1254659A4 (de) 2003-05-28
US20030212114A1 (en) 2003-11-13
DE60124504T2 (de) 2007-09-20
AU776851B2 (en) 2004-09-23
CA2400804A1 (en) 2001-08-09
CN1416341B (zh) 2010-05-05
EP1254659A1 (de) 2002-11-06
US7105572B2 (en) 2006-09-12
WO2001056562A1 (fr) 2001-08-09
CA2400804C (en) 2009-09-01
CN1416341A (zh) 2003-05-07

Similar Documents

Publication Publication Date Title
DE60124504D1 (de) Stabile emulsionszubereitungen
HUP0401303A2 (hu) Fungicid hatással rendelkező jódbenzopirán-4-on-származékok, előállításuk, alkalmazásuk és ilyeneket tartalmazó készítmények
HUP9802822A2 (hu) Halogén-benzimidazol-származékok, intermedierjeik, előállításuk és a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények
IL150650A0 (en) Piperidine derivatives and pharmaceutical compositions containing the same
NO20013379D0 (no) 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler
NO20004485D0 (no) Sykloalkenderivater, deres fremstilling og anvendelse
EA200200374A1 (ru) Производные хинолилпропилпиперидина, их получение и содержащие их композиции
ATE503746T1 (de) Neue imidazolidinderivate
ATE317691T1 (de) Benzochinonderivate enthaltende hemmer von nf-kb
DE60228316D1 (en) Xanthinoxidaseinhibitoren
ATE271045T1 (de) Sauerstoffhaltige heterocyclische verbindungen
WO2002024623A3 (en) Novel alkanoic acid derivatives
DK1447400T3 (da) Bicyklisk forbindelse
HUP0302193A2 (hu) 1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
FI923033A (fi) N-fenyltioureaderivat och farmaceutisk anvaendning
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
EA200200537A1 (ru) Оксимные о-эфирные соединения и фунгициды для применения в земледелии и садоводстве
BRPI0411664A (pt) composição oral antiplaca aquosa estável
BG105123A (en) Tetrahydroquinaline derivatives as glycine antagonists
KR970069989A (ko) 피리딘-2,3-디카르복실산 디아미드 유도체 및 유효성분으로 상기 유도체를 함유하는 제초제
ES2120498T3 (es) Nuevo compuesto tetraciclico.
MX9206930A (es) Nuevos compuestos
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
ATE367378T1 (de) Bis(2-aryl-5-pyridyl)derivate
DE60221250D1 (de) Bis(5-aryl-2-pyridyl)derivate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition